【Acticor Biotech-Product ACT017】Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Partner News

ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinicalstage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today that it will participate in the European Stroke Organization Conference (ESOC) 2023 on May 24, 25 and 26, 2023 in Munich, Germany.

At this conference, the Company presented three posters on the clinical development of glenzocimab:

1) Design of the ACTISAVE study (Abstract N°2314 – Poster n° P0511- session of May 25, 2023) Authors: Y. Pletan et al. This poster presents the methodology of the ACTISAVE study and the mapping of its global launch.

2) Sub-analysis of the ACTIMIS study – Glenzocimab Tolerance in association with antithrombotics (Abstract N°2314 – Poster n° P0507 – session of May 25, 2023) Authors: A. Peeters et al. This poster presents the results of a subgroup analysis of the ACTIMIS study in patients who received antithrombotic therapy in addition to glenzocimab. This sub-analysis confirms the very good safety profile of glenzocimab in these patients.

3) Sub-analysis of the ACTIMIS study – Patients over 80 years old (Abstract N°618 – e-Poster n° P1018 – session of May 24, 2023) Authors: S. Richard et al. This poster presents results of a subgroup analysis of the ACTIMIS study in patients over 80 years of age who received the standard of care (thrombolysis + thrombectomy). These patients are frequently excluded from clinical trials because they are at higher risk. The results of ACTIMIS indicate that glenzocimab does not present safety issues in these patients and shows a marked efficacy trend towards effectiveness in reducing disability and mortality.

Prior to this event, Acticor Biotech held a Scientific Committee meeting on Tuesday, May 23, 2023, to discuss the progress and prospects of the Phase 2/3 clinical trial, ACTISAVE, as well as the clinical study and registration plans for glenzocimab on the different continents. In addition, a round table for ACTISAVE investigators attending ESOC was held on Wednesday, May 24 to discuss the operational aspects of the trial. Professor Steve Watson (University of Birmingham) presented the history of the discovery of GPVI, the target of glenzocimab, and its antithrombotic properties without the risk of bleeding.

Sophie BINAY, Chief Operating Officer and Chief Scientific Officer, stated: “The posters presented at this key conference for stroke research and the holding of our Scientific Advisory Board and a round table discussion with the participation of numerous investigators and partners, underline the significant role played by Acticor Biotech in this ecosystem and the urgent need for new innovative treatments in stroke. We continue our efforts every day to develop our drug candidate glenzocimab to address the important medical challenge of stroke and cardiovascular emergencies in general.”

Original link: